09 Apr 2024 Christina Coughlin – AACR 2024 – AVA6000 data presentation Blogs | Investors | Podcasts and Videos | Therapeutics
09 Apr 2024 Avacta Therapeutics Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 at the AACR Annual Meeting Demonstrating Clinical Proof-of-Concept Showing Multiple Patient Responses Investors | Therapeutics
27 Mar 2024 Research and Development Spotlight Series – Episode 1 Blogs | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
06 Mar 2024 Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024 Therapeutics